Bayer Fights Bid To Invalidate Xarelto Blood Thinner Patent
German pharma giant Bayer has fired back at a bid from a Viatris subsidiary to invalidate a patent key to its blockbuster blood thinner Xarelto, marking the latest challenge from a...To view the full article, register now.
Already a subscriber? Click here to view full article